CD19 and neoplasm: Compared to imatinib, the enhanced efficacy of CD19@NP/17-DMAG with the broad-spectrum TKI may stem from increased exposure of tumor-specific neoantigens, eliciting a highly specific anti-tumor T-cell response 65-67.